Top Markets
#1 DogBull DogBull +36.28%
#2 The Bitcoin Bull The Bitcoin Bull +30.25%
#3 Siacoin Siacoin +27.47%
#4 Merlin's Seal BTC Merlin's Seal BTC +25.80%
#5 Pons Pons +20.43%
#6 MarsCoin MarsCoin +18.55%
#7 Ontology Gas Ontology Gas +18.26%
#8 Cash Cat Cash Cat +17.41%
#9 Akedo Akedo +12.86%
#10 Cryptopia Cryptopia +11.07%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Rank in Stocks #14772
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Share Price
$16.85
Last synced: 2023-07-07
Market Cap
$393.50M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CH
Trade VectivBio Holding AG (VECT)

Category

Healthcare
Revenue for VectivBio Holding AG (VECT)
Revenue in Sep 2026 TTM: 0
According to VectivBio Holding AG latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for VectivBio Holding AG from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH